公开(公告)号：US11865135B2

公开(公告)日：2024-01-09

申请号：US16466927

申请日：2017-12-05

Applicant: Innate Biotherapeutics, LLC

Inventor： Gabriel Oscar Reznik ,  John James Kane ,  James Michael Siedlecki ,  Zuzana Dostalova ,  Isabelle Sansal-Castellano ,  Ifat Rubin-Bejerano ,  Hua Miao ,  Eric Steven Furfine

IPC: A61K31/716 ,  A61K47/61 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K31/716 ,  A61K47/61 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/90

Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.

公开(公告)号：US10266609B2

公开(公告)日：2019-04-23

申请号：US15309313

申请日：2015-05-08

Applicant: Innate Biotherapeutics, LLC

Inventor： James Michael Siedlecki ,  Gabriel Oscar Reznik ,  John James Kane ,  Hua Miao ,  Arthur F. Kluge ,  Ifat Rubin-Bejerano

IPC: C07H1/00 ,  C08B37/00 ,  C07H3/06 ,  C07H5/04 ,  C07H13/04 ,  C07H15/04 ,  C07H15/18 ,  C07H15/203 ,  C07H15/26 ,  C07H19/044 ,  C07H19/048

Abstract: This invention relates to modifications of β-1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response.

公开(公告)号：US20200030360A1

公开(公告)日：2020-01-30

申请号：US16466927

申请日：2017-12-05

Applicant: Innate Biotherapeutics, LLC

Inventor： Gabriel Oscar Reznik ,  John James Kane ,  James Michael Siedlecki ,  Zuzana Dostalova ,  Isabelle Sansal-Castellano ,  Ifat Rubin-Bejerano ,  Hua Miao ,  Eric Steven Furfine

IPC: A61K31/716 ,  A61K47/61 ,  C07K16/28 ,  C07K16/32

Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.